The Coxsackie-Adenovirus Receptor (CAR) Is Used by Reference Strains and Clinical Isolates Representing All Six Serotypes of Coxsackievirus Group B and by Swine Vesicular Disease Virus  by Martino, Tami A. et al.
S
r
t
l
Virology 271, 99–108 (2000)
doi:10.1006/viro.2000.0324, available online at http://www.idealibrary.com onThe Coxsackie-Adenovirus Receptor (CAR) Is Used by Reference Strains
and Clinical Isolates Representing All Six Serotypes of Coxsackievirus
Group B and by Swine Vesicular Disease Virus
Tami A. Martino,*,† Martin Petric,†,‡ Hana Weingartl,§ Jeffrey M. Bergelson,¶ Mary Anne Opavsky,*,i
Christopher D. Richardson,** John F. Modlin,†† Robert W. Finberg,‡‡ Kevin C. Kain,i
Norman Willis,§ Charles J. Gauntt,§§ and Peter P. Liu*,i ,1
*Heart and Stroke/Richard Lewar Center of Excellence, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, EC12-324, Toronto,
Ontario M5G 2C4, Canada; ‡The Virology Laboratory, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, 555 University
Avenue, Toronto, Ontario M5G 1X8, Canada; †Department of Molecular and Medical Genetics and Microbiology and iDepartment of Medicine,
University of Toronto, Toronto, Ontario, Canada; §National Center for Foreign Animal Diseases, 1015 Arlington Street, Suite T2300, Winnipeg,
Manitoba R3E 3M4, Canada; ¶Division of Immunologic and Infectious Diseases, Children’s Hospital of Philadelphia, 34th Street and Civic Center
Boulevard, Philadelphia, Pennsylvania 19104; **Amgen Research Institute, 620 University Avenue, Suite 706, Toronto, Ontario M5G 2C1, Canada;
††Dartmouth Medical School, One Medical Center Drive, Lebanon, New Hampshire 03756; ‡‡Dana Farber Cancer Institute, 44 Binney Street,
Boston, Massachussetts 02115; and §§Department of Microbiology, The University of Texas Health Science Center
at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284-7758
Received December 22, 1999; returned to author for revision March 13, 2000; accepted March 20, 2000
Group B coxsackieviruses are etiologically linked to many human diseases, and cell surface receptors are postulated to
play an important role in mediating their pathogenesis. The coxsackievirus adenovirus receptor (CAR) has been shown to
function as a receptor for selected strains of coxsackievirus group B (CVB) serotypes 3, 4, and 5 and is postulated to serve
as a receptor for all six serotypes. In this study, we demonstrate that CAR can serve as a receptor for laboratory reference
strains and clinical isolates of all six CVB serotypes. Infection of CHO cells expressing human CAR results in a 1000-fold
increase in CVB progeny virus titer compared to mock transfected cells. CAR was shown to be a functional receptor for swine
vesicular disease virus (SVDV), as CHO-CAR cells but not CHO mock transfected controls were susceptible to SVDV infection,
produced progeny SVDV, and developed cytopathic effects. Moreover, SVDV infection could be specifically blocked by
monoclonal antibody to CAR (RmcB). SVDV infection of HeLa cells was also inhibited by an anti-CD55 MAb, suggesting that
this virus, like some CVB, may interact with CD55 (decay accelerating factor) in addition to CAR. Finally, pretreatment of CVB
or SVDV with soluble CAR effectively blocks virus infection of HeLa cell monolayers. © 2000 Academic PressKey Words: enterovirus; coxsackievirus B; swine vesicular disease virus; Coxsackievirus adenovirus receptor (CAR); decay
accelerating factor (DAF; CD55).INTRODUCTION
Group B coxsackieviruses are etiologically implicated
in human disease whose clinical manifestations include
mild gastrointestinal or upper respiratory tract symp-
toms, myocarditis, meningitis, encephalitis, and pulmo-
nary disease (Chonmaitree and Mann, 1995; Grist et al.,
1978; Liu et al., 1996; Martino et al., 1995a,b; Rotbart,
1995; Woodruff, 1980). Infection is mediated by cell sur-
face receptors, which facilitate binding and entry of CVB
into susceptible host cells. Receptors may have a major
role in determining organ and cell tropism in patients
infected with these viruses and may account for some of
1 To whom reprint requests should be addressed at Heart and
troke/Richard Lewar Center of Excellence, University of Toronto, To-
onto General Hospital, 200 Elizabeth Street, EC12-324, Toronto, On-
ario, Canada, M5G 2C4. Fax: (416) 340-4753. E-mail: peter.
iu@utoronto.ca.
99the clinical manifestations and disease sequelae (Crow-
ell and Landau, 1983; Holland, 1961; Rotbart and Kirkeg-
aard, 1992).
It had been proposed that all CVB1-6 serotypes shared
a common receptor molecule. This hypothesis was
based on the observation that prototype strains of
CVB1-6 competed with each other for binding to the
HeLa cell surface but did not interfere with cell binding
by other enterovirus types (Lonberg-Holm et al., 1976). A
monoclonal antibody termed RmcB, directed against this
putative common receptor molecule, was subsequently
shown to block binding and infection by CVB reference
strains (Hsu et al., 1988). However, it was also demon-
strated that RmcB blocked only some clinical isolates of
CVB from infecting HeLa cells (Bergelson et al., 1997b),
throwing into question the nature of MAb blocking stud-
ies and the premise of the common CVB receptor mole-
cule.
A common receptor molecule termed the coxsackievi-
0042-6822/00 $35.00
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100 MARTINO ET AL.rus adenovirus receptor (CAR) was recently cloned and
characterized. It functions as a cell surface receptor for
CVB, as well as an attachment molecule for adenovirus
fiber proteins (Bergelson et al., 1997a; Carson et al., 1997;
oelvink et al., 1998; Tomko et al., 1997). CAR is a 46-kDa
ransmembrane glycoprotein with two extracellular im-
unoglobulin-like domains. Selected strains of CVB3
nd CVB4 and CVB5 were shown to bind and to produc-
ively infect nonsusceptible hamster cells transfected
ith CAR cDNA but not control cells lacking the CAR
olecule (Bergelson et al., 1997a; Tomko et al., 1997).
It still remains to be proven that CAR can function as
a common host cell receptor for CVB. In this study, we
have tested whether CAR functions as a receptor for a
variety of clinical and prototype isolates representing the
six CVB serotypes. In addition we have examined
whether swine vesicular disease virus (SVDV), which is
antigenically and genetically related to CVBs (Graves,
1973; Martino et al., 1999; Zhang et al., 1993, 1999), is
capable of utilizing the same CVB receptors, namely CAR
and DAF.
RESULTS
Confirmation of CAR mRNA in cells
We first confirmed that the cell lines used in this study
that were susceptible to virus infection expressed CAR
RNA, while cell lines not susceptible to virus did not
express CAR. CAR transcription was monitored by RT–
PCR analysis using CVB-susceptible HeLa cells, Vero
cells, and transiently transfected CHOP-CAR cells and
the nonsusceptible untransfected CHOP cells. We also
examined the SVDV-susceptible porcine cell lines ST
and PK-15. Figure 1 is a composite picture demonstrating
that CAR cDNA was amplified from all the cell lines that
FIG. 1. Amplification of CAR mRNA by RT–PCR. PCR products were
lectrophoresed on 1.5% EtBr agarose gels. Lanes 1 and 6 contain the
NA marker GeneRuler 1 kb (MBI Fermentas). The lowest five bands
hown denote DNA sizes of 500, 750, 1000, 1500, and 2000 bp, as per
he manufacturer’s specifications. Lanes 2–5, 7, and 8 contain a 10-ml
liquot of each PCR reaction mix. Lane 2, HeLa cells; lane 3, Vero cells;
ane 4, CHOP cells transfected with CAR cDNA; lane 5, control CHO
ells; lane 7, porcine ST cells; lane 8, porcine PK-15 cells. The major
and at ;1.1 kb (arrow) is the anticipated size of the amplicon contain-
ng the coding region of CAR.were susceptible to CVB (HeLa, Vero, CHOP-CAR) and
SVDV (ST, PK-15) but not from nonsusceptible untrans-fected CHOP cells. Although not shown, positive controls
using cloned CAR cDNA were run along with the original
PCR reactions and were consistently positive as ex-
pected. Also, negative water controls containing all re-
agents except for CAR cDNA were consistently negative.
PCR amplification of the entire coding region of CAR
produced a DNA product that ran just above 1 kb on gel
analysis (Fig. 1, see arrow), consistent with the ;1.1 kb
size of the mRNA coding region of CAR (Bergelson et al.,
1997a; Tomko et al., 1997).
CVB induces cytopathic effect on CAR-positive cells
All CVB strains tested induced cytopathic effect (CPE)
on monolayers of HeLa cells and stably transfected
CHO-CAR cells (Table 1 and Fig. 2). Some CVB strains
also produced CPE on Vero cell monolayers, although
only CVB5 (Faulkner), CVB3cs-N, CVB3cs-NR, and
CVB3cs-20 were observed to produce a comparable CPE
in Vero cells as they did in HeLa cells (not shown).
Genetically manipulated chimeric viruses generated
from the cardiovirulent CVB3cs-CG strain and the aviru-
lent CVB3cs-Ø strain (Lee et al., 1997) also produced
CPE on monolayers of HeLa cells and stable CHO-CAR
cells (not shown). In contrast, none of the CVBs caused
CPE in CHO-control cells lacking the CAR receptor mol-
ecule. The control enteroviruses, coxsackievirus A9 and
echovirus 9, did not cause CPE on any cell line tested
(Table 1 and Fig. 2).
CVB1-6 reference strains, wild-type clinical isolates,
and laboratory variants produce progeny virus in
transiently transfected CHOP-CAR cells
The yield of reference CVB1-6 strains was 3–6 logs
greater in transiently transfected CHOP-CAR cells as
compared to control CHOP cells transfected with partial
CAR sequence cDNA or to mock transfected cells (Fig.
3a). Similarly, the yield of all nine clinical CVB isolates
was 2–3 logs greater in cells expressing the entire CAR
protein as compared to controls (Fig. 3b). Finally, the
yield of the six CVB3 strains known to be cardiovirulent
in mice was 2–6 logs greater in cells expressing full-
length CAR as compared to control cells (Fig. 3c). These
results indicate that all CVB1-6 strains tested use CAR as
a functional cellular receptor.
Small amounts of virus could be detected at 24 h in
control cell cultures infected with CVB clinical isolates
and cardiovirulent variants CVB3-N, CVB3-NR, and
CVB3-20 (Figs. 3b and 3c). To confirm that this was not
due to virus replication in control cells, we compared
virus titers at 24 h and 1 h p.i. Virus titers were generally
unchanged or lower at 24 h as compared to those de-
tected immediately after virus absorption with the excep-
tion of a few clinical isolates (Figs. 3b and 3c). However,
even for these isolates, virus titer changes were never as
substantive as when the cells were expressing the CAR
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101CAR IS RECEPTOR FOR CVB SEROTYPES AND REFERENCE STRAINSreceptor. Moreover, CPE was never detected in control
CHO cell monolayers for any of the virus strains tested
(Table 1). Based on these observations, we believe that
the low virus titers in control cultures at 24 h p.i. most
likely reflects residual input virus from the inoculum.
Since the cell monolayers were washed three times, it is
unclear as to whether further washing would help to
decrease the residual virus levels. It is tempting to spec-
ulate that they may even remain constant because of
interactions between some virus strains and the CHO
cell surface. A previous report of a putative molecule on
CHO cells that interacts with the cardiovirulent CVB3-N
strain but does not allow for productive lytic infection
provides some support for this hypothesis (Kramer et al.,
1997).
SVDV utilization of CAR and DAF receptors
Strong antigenic and phylogenetic relationships be-
tween CVB and swine vesicular disease virus (SVDV) led
us to examine if CAR can serve as a functional receptor
for SVDV. As shown in Table 1 and Fig. 2, SVDV infection
d CVB3 that are cardiovirulent in mice, as described in Martino et al.
(1998).
‡ Specimens isolated at the Hospital for Sick Children, Toronto, Canada.
* Specimens described in Bergelson et al. (1997b), maintained in the
FIG. 2. Virus-induced cytopathic effect on CAR-positive cells. Stable
CHO-CAR transfectants or CHO-control cells plated in 96-well Costar
dishes at a density of 6 3 104 cells/well were incubated with 50 ml of
erial twofold dilution’s of each test virus (10-fold dilution’s for SVDV) at
oom temperature for 1 h. Monolayers were washed, and growth
edium was added for 3 days. To monitor for CPE, cell monolayers
ere fixed in 2% Formalin and stained with a 2% formaldehyde/0.1%
rystal violet dye solution. Panels 1 and 5, CVB3-VR30 (Nancy); panels
and 6, SVDV; panels 3 and 7, EV9; panels 4 and 8, CAV9.TABLE 1
Cytopathic Effect in Designated Cell Linesa
Virus
Cell line
HeLa CHO-CAR bCHO
Reference strainsc
CVB1 (Conn-5) 1 1 2
CVB2 (Ohio) 1 1 2
CVB3 (VR30-Nancy) 1 1 2
CVB3-N (RLC)* 1 1 2
CVB4 (Benschoten) 1 1 2
CVB5 (Faulkner) 1 1 2
CVB6 (Schmitt) 1 1 2
ardiovirulent CVB3d
CG 1 1 2
SH 1 1 2
B 1 1 2
N 1 1 2
NR 1 1 2
20 1 1 2
linical isolates
CVB1 (5010107)‡ 1 1 2
CVB1 (5010607)‡ 1 1 2
CVB1 (86-2299)* 1 1 2
CVB1 (94-0503)* 1 1 2
CVB1 (95-0004)† 1 1 2
CVB2 (5010159)‡ 1 1 2
CVB2 (90-1376)* 1 1 2
CVB2 (90-1445)* 1 1 2
CVB3 (4012530)‡ 1 1 2
CVB3 (19141255)‡ 1 1 2
CVB3 (19281109)‡ 1 1 2
CVB3-R (20270361)‡ 1 1 2
CVB3 (20310308)‡ 1 1 2
CVB3 (86-1799)* 1 1 2
CVB3 (86-1990)* 1 1 2
CVB3 (86-2327)* 1 1 2
CVB3 (86-2424)* 1 1 2
CVB3 (86-2751)* 1 1 2
CVB3 (95-003)† 1 1 2
CVB4 (5010936)‡ 1 1 2
CVB4 (87-1026)* 1 1 2
CVB4 (88-0658)* 1 1 2
CVB4 (88-0842)* 1 1 2
CVB5 (88-0578)* 1 1 2
CVB5 (88-0870)* 1 1 2
CVB5 (88-0973)* 1 1 2
CVB5 (89-0895)* 1 1 2
CVB5 (89-0516)† 1 1 2
CVB6 (95-0005)† 1 1 2
CVB6 (95-0006)† 1 1 2
CAV9 (4012720)‡ 2 2 2
EV9 (22030957)‡ 2 2 2
wine vesicular disease virus
SVDV UK 27/72 1 1 2
a Experiments were performed as described in Fig. 2.
b Enterovirus specimens maintained in the laboratory of P.P.L. and
SVDV were tested on CHO-control cells transfected with empty
pcDNA3.1 vector. CVBs maintained in the laboratory of J.F.M. were
tested on CHO-control cells transfected with human integrin a2 sub-
nit.
laboratory of J.F.M.
† Additional specimens from the laboratory of J.F.M.
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102 MARTINO ET AL.produced cytopathic effects on monolayers of stably
transfected CHO-CAR cells and on monolayers of HeLa
cells. In addition, SVDV produced CPE on monolayers of
porcine ST and PK-15 cells from which a CAR homolog
was amplified by PCR (Fig. 1). In contrast, no SVDV CPE
was observed in the receptor-negative CHO-control cells
(Table 1 and Fig. 2). Anti-CAR MAb RmcB decreased
SVDV plaque formation by ;75% in stably transfected
HO-CAR cells and in HeLa cells (Table 2 and Fig. 4). In
ontrast, control serum did not decrease SVDV plaque
ormation.
DAF is a coreceptor molecule used by some CVB
trains (Bergelson et al., 1995; Martino et al., 1998;
Shafren et al., 1995). Previous studies have shown that
HeLa cells express DAF at the cell surface and that
anti-DAF antibodies specifically block CVB interactions
with DAF on HeLa cells (Bergelson et al., 1995, 1997b;
Martino et al., 1998; Crowell et al., 1986; Mohanty and
rowell, 1993; Shafren et al., 1995). Because SVDV, like
he CVBs, was able to use the CAR receptor, its ability to
lso use DAF as a receptor was explored. As shown in
able 2, pretreatment of HeLa cell monolayers with anti-
AF MAb 914 resulted in a reduction of SVDV yield by
5%. The antibody to DAF was therefore as efficient at
uppressing the replication of SVDV as antibody to CAR.
hese findings are consistent with the hypothesis that,
s is the case for CVB1, -3, -5, both DAF and CAR have
eceptor functions.
oluble CAR blocks CVB3 and SVDV infection of
eLa cells
To examine whether CAR alone can block virus infec-
ion of cells, we produced a soluble form of the CAR
olecule (sCAR) and demonstrated that it is a specific
nhibitor of CVB and SVDV infection. sCAR lacking the
ransmembrane and cytoplasmic domains was produced
y fusing DNA encoding the extracellular portion of CAR
o DNA encoding the Fc region of rabbit immunoglobulin.
he DNA was inserted into a eukaryotic expression vec-
or and transiently transfected into 293 cells. sCAR se-
reted into the supernatant was purified by chromatog-
aphy. The ability of sCAR to inhibit CVB and SVDV
nfection of cells was examined using a quantitative in
itro assay for virus cytopathic effect (CPE). sCAR was
reincubated with virus, and then the mixture was added
FIG. 3. CVB1-6 reference strains, clinical isolates, and cardiovirulen
Costar dishes at a density of 2.5 3 105 cells/well were transfected w
eagent for 5 h, were washed, and were incubated overnight in growth m
f 5 PFU/cell at room temperature for 1 h. Monolayers were washed,
noculum) or 24 h at 37°C (to allow for progeny virus production). Dish
irus titer was monitored by TCID50 assay on HeLa cells. HCAR7, full-
HOP T 5 0 h or T 5 24 h, mock transfected cells inoculated with virtriplicate. (A) Progeny production by CVB1-6 reference strains. (B) Progen
cardiovirulent CVB3.o HeLa cell monolayers. As shown in Fig. 5, sCAR
locked CVB3- and SVDV-induced CPE on the HeLa cell
onolayers in a dose-dependent manner. In contrast, a
ontrol immunoadhesin consisting of avian leukosis vi-
us envelope glycoprotein fused to rabbit Fc (ALV–env)
id not block virus infection of the cells.
DISCUSSION
In these studies, evidence is provided that reference
trains and clinical isolates representing all six sero-
ypes of group B coxsackieviruses (CVB) interact with the
oxsackievirus adenovirus receptor (CAR) during infec-
ion. All CVB strains were capable of replicating and
ausing CPE in hamster cells expressing CAR but not
AR-negative control cells. In contrast, other enterovi-
uses such as coxsackievirus A9 and echovirus 9 did not
nfect CAR-expressing cells. These findings are consis-
ent with the hypothesis that all CVB use a common
eceptor molecule (Bergelson et al., 1997a; Hsu et al.,
988; Lonberg-Holm et al., 1976). Moreover, use of CAR
y CVB clinical isolates strongly suggests that CAR may
e a CVB receptor in vivo. Virus strains isolated by only
ne passage through primary GMK cells were capable of
tilizing CAR as well as virus strains that had been
aintained for many years in cell culture.
In these experiments, CAR was shown to be a func-
ional receptor for all CVB strains tested. In a previous
tudy using a panel of CVB clinical and prototype iso-
ates (Bergelson et al., 1997b), it was found that infection
y many—but not by all—isolates was inhibited by the
nti-CAR MAb RmcB. Eighteen of these isolates were
ubsequently shown to infect stably transfected CHO-
AR cells and CHO-control cells, and all were found to
se CAR as a receptor. Why some of these viruses are
ot inhibited by RmcB is not certain. It is possible that
hey interact with CAR in a way that cannot be inhibited
terically by RmcB; it is also possible that they make use
f additional receptor molecules. Coreceptors or acces-
ory molecules for CVBs that have been identified to
ate include decay accelerating factor (Bergelson et al.,
995; Shafren et al., 1995) and the integrin avb6 (Agrez et
al., 1997). Two additional putative receptors are a 100-
kDa nucleolin-like membrane protein (Raab de Verdugo
et al., 1995) and a hamster cell binding molecule (Kramer
nts replicate in CAR transfected cells. CHOP cells plated on 24-well
g/well of CAR cDNA (or controls) using 2.5 ml/well of Lipofectamine
. CAR transfected cells were inoculated with each test virus at an m.o.i.
lls were further incubated for 0 h (to monitor for residual virus in the
taining cells and progeny virus were frozen and thawed, and progeny
CAR cDNA clone; HCAR2, cDNA control coding for AA 1–189 of CAR.
incubated for 0 or 24 h, respectively. Experiments were performed int varia
ith 1.6 m
edium
and ce
es con
length
us andy production by CVB clinical isolates. (C). Progeny production by
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104 MARTINO ET AL.et al., 1997), although a role for these molecules in CVB
infections in humans is not known.
Previous studies have indicated that SVDV is antigeni-
cally and phylogenetically related to CVB and may have
arisen within the past century from a single transfer of
CVB5 into pigs (Graves, 1973; Zhang et al., 1993, 1999).
These observations prompted us to examine whether
SVDV could use the CVB receptor CAR. We found that
SVDV could replicate and cause CPE in hamster cells
expressing CAR but not mock transfected cells lacking
CAR. Moreover, pretreatment of CAR-positive cells with
anti-CAR monoclonal antibody RmcB blocked virus infec-
tion in plaque assays. These observations indicate that
CAR can serve as a functional receptor for SVDV, a
TABLE 2
Anti-CAR and Anti-DAF MAbs Block SVDV Infectivitya
Cell line
% SVDV plaque reduction
Anti-CAR
RmcB
Anti-DAF
MAb 914
Anti-albumin
(control)
HO-CAR 72 6 7 n/a 6 6 1
eLa 72 6 15 75 6 5 9 6 7
a CHO-CAR or HeLa cells plated in six-well Costar dishes at a
ensity of 1 3 106 cells/well were preincubated with 1 ml of medium
ontaining 1:1000 dilution RmcB antibody as described previously (Ber-
elson et al., 1997) or 50 mg/ml anti-DAF MAb 914 (Martino et al., 1998)
or 50 mg/ml of control rabbit anti-bovine albumin antiserum, at room
temperature for 1 h. After washing, 1 ml containing ;50 PFU/ml of
SVDV was added and cells were incubated at room temperature for 1 h.
Monolayers were washed, plaque overlays were added for 2-3 days,
and the plaques were counted. All experiments were performed in
triplicate.
FIG. 4. Inhibition of SVDV plaque formation on CHO-CAR cells pre-
reated with anti-CAR MAb RmcB. CHO-CAR cells plated in 6-well
ostar dishes at a density of 1 3 106 cells/well were preincubated with
1 ml medium containing a 1:1000 dilution of RmcB ascites (or controls)
at room temperature for 1 h. After washing, 1 ml containing ;50 PFU/ml
of SVDV was added at room temperature for 1 h. The monolayers were
washed, plaque overlays were added for 36 h, then cells were stained
with crystal violet dye solution. Upper wells, plaques on CHO-CAR cell
monolayers pretreated with anti-CAR MAb RmcB, then infected with 50
PFU SVDV. Lower wells, plaques on untreated CHO-CAR monolayers
infected with 50 PFU SVDV only.characteristic shared only with CVBs to date. It is tempt-
ing to speculate that the ability of SVDV to use CAR is an
inherent characteristic from the evolutionary past that
may have facilitated virus entry into porcine hosts. In-
deed, when two porcine cell lines commonly used in
SVDV propagation were examined by PCR, they both
were found to express CAR RNA. Porcine CAR tran-
scripts have also been detected recently in pig liver
tissue (Fechner et al., 1999). Porcine CAR seems a likely
candidate receptor for SVDV in pigs, and future transfec-
tion studies with this molecule are indicated to resolve
this concept. Moreover, interactions of CVBs with por-
cine CAR homolog could provide further insight into
receptor interactions with these viruses. This may also
be of some concern in xenotransplantation of porcine
organs.
Our studies provide evidence that SVDV also uses the
CVB receptor molecule DAF. We found that pretreatment
of DAF-positive HeLa cells with anti-DAF monoclonal
antibody decreased SVDV infection by 75% in plaque
assays, suggesting that DAF may be a coreceptor mol-
ecule. Binding studies such as those done with CVB
(Bergelson et al., 1995; Martino et al., 1998; Shafren et al.,
1995) would help define the nature of this receptor inter-
action and confirm that there are specific interactions
and that the blocking is not just due to steric hindrance.
DAF receptor usage may also be a characteristic re-
tained from the evolution of CVB5 into SVDV, although it
is not known whether a homolog of human DAF is ex-
pressed in pigs. The SVDV UK/27/72 strain used for this
FIG. 5. Soluble CAR (sCAR) decreases CVB3 and SVDV induced
cytopathic effect on CAR-positive HeLa cells. HeLa cells were plated in
96-well dishes at a density of 3 3 104 cells/well and incubated over-
ight under standard culture conditions. CVB3 (strain Nancy from Dr.
ichard Crowell, as described in Bergelson et al., 1995) or SVDV was
iluted in a-MEM medium to 1 or 10 m.o.i. and was added to 1 or 2 mg
of sCAR (or ALV–env as control), and samples were incubated for at
37°C for 1 h. Medium from the cell wells was removed and was
replaced with the mixtures of virus and sCAR protein (or controls), in
duplicate wells. CPE was monitored after 24 h by fixing cell monolayers
with crystal violet dye solution.study was collected in 1972 and was one of the first
isolates reported. It would be interesting to determine
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105CAR IS RECEPTOR FOR CVB SEROTYPES AND REFERENCE STRAINSwhether DAF receptor usage is also retained in more
recent SVDV strains.
These experiments confirm that all CVBs share a com-
mon host cell receptor. The fact that clinical isolates use
CAR as a receptor suggest that CAR may function as a
receptor in the host and that it may play an important role
in the pathogenesis of coxsackievirus disease. The role
in pathogenesis of possible coreceptors such as DAF
remains poorly understood, and the relation between
virus tropism and tissue-specific receptor expression
remains to be defined. Since it appears that CAR is the
major receptor for CVB, structural studies of virus–CAR
interaction could be important in the development of new
antiviral agents. Also, soluble CAR decreases virus in-
fection of host cells, possibly opening new avenues for
treating CVB- and SVDV-induced disease.
MATERIALS AND METHODS
Cell lines
HeLa cells (CCL-2) and Vero cells (CCL-81) were ob-
tained from the American Type Culture Collection
(ATCC). They were grown in RPMI 1640 medium supple-
mented with 0.5% penicillin and streptomycin and 10%
fetal calf serum (FCS). CHOP (Chinese hamster ovary)
cells were from the laboratory of Dr. Jim Dennis (Heffer-
nan and Dennis, 1992) and used for transient transfec-
tion of CAR cDNA (CHOP-CAR) or control cDNAs. Tran-
siently transfected CHOP-CAR cells were grown in
DMEMa medium supplemented with 0.5% penicillin and
treptomycin and 10% FCS. CHO-CAR cells are CHO
ells stably transfected with CAR cDNA (Bergelson et al.,
997a), and CHO-control cells are stably transfected with
mpty pcDNA3.1 vector (Wang and Bergelson, 1999) or
ith human integrin a2 subunit (Bergelson et al., 1993).
table CHO-CAR transfectants and CHO-control cells
ere cultured in nucleoside-free alpha minus MEM sup-
lemented with NaHCO3 to pH 7.5, 0.5% penicillin and
treptomycin, and 10% FCS. GMK cells (primary tube
ultures of African green monkey kidney) were obtained
rom Viromed, Minneapolis, MN. They were cultured in
LY medium (Earle’s balanced salt solution, supple-
ented with lactalbumin, yeast hydrolysate, and 0.5%
enicillin and streptomycin). Swine testis (ST) cells were
btained from the ATCC. Porcine kidney (PK-15) cells
ere from NVLS, Ames, IA. ST and PK-15 cells were
aintained in alpha MEM supplemented with 0.5% gen-
amicin and 10% FCS. Media and supplements were
urchased from Gibco/BRL Life Technologies Canada,
urlington, Ontario, Canada.
iruses
Reference virus strains CVB1 (Conn-5), CVB2 (Ohio),
VB3-VR30 (Nancy), CVB4 (Benschoten), CVB5
Faulkner), and CVB6 (Schmitt) were obtained from ATCC.
oirus stocks were prepared by one passage in HeLa
ells (with Vero cells used for CVB6). Stocks were frozen
nd thawed three times, were clarified by centrifugation,
ere titred by plaque assay on HeLa cells, and were
tored as aliquots at 270°C. Enterovirus isolates col-
ected over a 5-year period at the Hospital for Sick
hildren, Toronto, Canada are shown in Table 3. These
iruses were isolated by culture on GMK cells and were
yped using diagnostic antisera at the Canadian National
entre for Enteroviruses, Halifax, Canada. Additional
VB clinical specimens were maintained in the labora-
ory of J.F.M., and some of these samples were described
reviously by Bergelson et al., 1997b (see Table 1). CVB3
strains known to be cardiovirulent in mice (CVB3cs) -SH,
-NR, -N, -CG, -20, and -Ø were maintained in our labo-
ratory, as previously described (Martino et al., 1998).
VDV (UK 27/72) was obtained from the Institute for
nimal Health, Pirbright, UK, and maintained at the Na-
ional Center for Animal Diseases, Winnipeg, Manitoba,
anada.
ntibodies
Anti-CAR RmcB monoclonal antibody was prepared as
ouse ascites fluid (Hsu et al., 1988) and was provided
y J.M.B. Anti-CAR rabbit polyclonal antiserum was pre-
ared as described below. Anti-DAF MAb 914 (clone
RIC 216) was obtained from Serotec Canada, Toronto,
ntario, Canada. Rabbit affinity purified anti-bovine albu-
in antiserum was obtained from Cappel/ICN, Toronto,
ntario, Canada.
rimers
Primer TM39 was used for first-strand cDNA synthesis
f CAR. TM39 (59-TTGAGGCTAGTAACACAAT-39) was de-
ived from the CAR 39 nontranslated region (Bergelson et
l., 1997a). Primers TM31 and TM32 were used for PCR
TABLE 3
Enterovirus Isolates from Patients at the Hospital
for Sick Children, Toronto, Canada
Virus type Specimen Year isolated isolate number
CVB1 CSF 1995 CVB1 (5010107)
CVB1 Throat swab 1995 CVB1 (5010607)
CVB2 CSF 1995 CVB2 (5010159)
CVB3 Stool 1994 CVB3 (4012530)
CVB3 Stool 1997 CVB3 (19141255)
CVB3 Stool 1997 CVB3 (19281109)
CVB3 Pleural fluid 1998 CVB3 (20270361)
CVB3 Stool 1997 CVB3 (20310308)
CVB4 CSF 1995 CVB4 (5010936)
CVB9 CSF 1994 CAV9 (4012720)
EV9 CSF 1997 EV9 (22030957)f CAR. Primer TM31 (59-ACTTATCTAGGATCCATG-
GCGCTCCTGCTGTGCTTCGTGCTCCTGTGC-39) consists
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106 MARTINO ET AL.of a BamHI restriction site (underlined), followed by the
first 33 nucleotides encoding hCAR protein (Bergelson et
al., 1997a). Primer TM32 (59-CGTTATGTACTCGAGC-
CTATACTATAGACCCATCCTTGCTCTGTGCTGG-39) con-
sists of an XhoI restriction site (underlined), a single
cytosine nucleotide, and 33 nucleotides complementary
to the CAR coding sequence upstream of the termination
codon (Bergelson et al., 1997a).
PCR amplification of CAR cDNA
RNA extracted from HeLa, Vero, transiently transfected
CHOP-CAR cells, untransfected CHOP cells, and the
porcine cells lines ST and PK-15 was subjected to re-
verse transcription followed by PCR to amplify the CAR
cDNA. Total cell RNA was purified using TRIzol reagent
according to the manufacturer’s directions (Gibco BRL).
For first-strand cDNA synthesis, a 15-ml aliquot of RNA
as heated for 5 min at 65°C, was chilled on ice, then
as added to a 25-ml volume containing 1[mult] AMV
everse transcription buffer (Pharmacia), 1 ml RNasin
Pharmacia), 4 ml of 10 mM dNTP mixture (Pharmacia), 2
ml of 10 mM spermidine HCl, 2 ml of 80 mM sodium
yrophosphate, 4 ml of downstream primer TM39, and 1
ml of AMV reverse transcriptase (Pharmacia). Samples
were incubated at 37°C for 1 h. For PCR, a 4-ml aliquot of
his reaction mixture was added to a 46-ml volume con-
taining 1[mult] reaction buffer (Pharmacia Biotech Inc.,
Baie d’Urfe, Quebec, Canada), 0.2 mM of dNTP (Pharma-
cia), and 2 mM each of primers TM31 and TM32. The
preparation was denatured for 10 min at 94°C, then 2.5 U
of Taq polymerase (Pharmacia) and 50 ml light mineral oil
ere added. PCR was performed on a DNA Thermal
ycler (Perkin–Elmer Cetus) for 39 cycles of annealing
0°C, 2 min; extension 72°C, 2 min; and denaturation
4°C,1 min.
xpression of CAR and production of rabbit
olyclonal antisera
HeLa cell CAR cDNA was amplified by PCR and puri-
ied by agarose gel electrophoresis. A band correspond-
ng to the ;1.1-kb coding region of CAR was excised
rom the gel and was purified with Sephaglas Band Prep
Pharmacia), was digested with BamHI and XhoI (Phar-
macia), was ligated into a pET28a(1) cloning vector
(Novagen, Madison, WI), and was transformed into
INVaF9 One Shot cells (Invitrogen, Carlsbad, CA). The
resence of CAR in the transfected cells was confirmed
y extraction and purification of hCAR-pET28a(1) DNA
n Qiagen chromatography columns (Qiagen Inc, Santa
larita, CA), and by sequencing the CAR portion using
hermosequenase (Amersham Canada Ltd, Oakville,
ntario, Canada). Full-length in-frame clones were trans-
ormed into BL21(DE3) expression host cells (Novagen).
o induce CAR protein expression, transformed cells
ere grown in the presence of IPTG, in accordance withhe manufacturer’s instructions (Novagen). Proteins ex-
racted from these cells were fractionated by SDS–PAGE
nalysis and were transferred electrophoretically to a
olyvinylidene fluoride (PVDF) nylon membrane (Milli-
ore, Bedford, MA). A band corresponding to CAR pro-
ein was detected by Western blot immunohistochemical
nalysis, using a 1:3000 dilution of T7*Tag antibody-
lkaline phosphatase conjugate (Novagen) and BCIP-
BT (5-bromo-4chloro-3indolyl phosphate-nitro blue tet-
azolium; SigmaFAST, Sigma Chemicals). Rabbit poly-
lonal antisera were then raised against the CAR protein.
DS–PAGE gel bands corresponding to expressed CAR
rotein were excised, were soaked in PBS to remove
taining solutions, were mixed with Freund’s incomplete
djuvant, and were injected subcutaneously into two
oung adult male rabbits once every 2 weeks for six
uccessive weeks. Sera collected from these animals
as stored at 220°C. Reactivity to CAR was confirmed
y Western blot and flow cytometry analysis using HeLa
ells or CHO cells transfected with CAR cDNA as de-
cribed below.
AR expression in eukaryotic cells and CVB
eplication in transfected cells
HeLa cell CAR cDNA (1.1 kb) amplified by PCR was
igested with BamHI and XhoI restriction endonucle-
ses (Pharmacia), was ligated into pcDNA-1.1/Amp
ector (Invitrogen), and was transformed into INVaF9
One Shot cells (Invitrogen). hCAR-pCDNA-1 was puri-
fied by Qiagen chromatography (Qiagen Inc) and was
sequenced by Thermosequenase (Amersham Canada
Ltd.). Two clones were selected of which one, hCAR7,
contained full-length coding sequence and the other,
hCAR2, encoded the extracellular region only (amino
acids 1–189). CHOP cells were transfected with
hCAR7-pcDNA-1 or hCAR2-pcDNA-1 or mock trans-
fected, using Lipofectamine reagent (Gibco/BRL Life
Technologies Canada, Burlington, Ontario, Canada)
according to the manufacturer’s instructions. CAR ex-
pression was monitored by immunohistochemical
staining and Western blot analysis of transfected cells,
using rabbit anti-CAR polyclonal antibody. Transfec-
tion efficiency was also monitored using a reporter
vector containing GFP (jellyfish green fluorescent pro-
tein) (kindly supplied by Dr. Peter Backx, University of
Toronto, Canada). CVB replication in transiently trans-
fected CHOP-CAR cells (or controls) was monitored by
inoculating cell monolayers with each test virus at
room temperature for 1 h, washing three times, and
further incubating in growth medium for 0 h (to monitor
for residual virus in the inoculum) or 24 h at 37°C.
Dishes containing cells and virus were frozen and
thawed, and progeny virus titer was determined by
TCID50 assay on HeLa cells.
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107CAR IS RECEPTOR FOR CVB SEROTYPES AND REFERENCE STRAINSCVB-induced cytopathic effect on CAR-positive cells
Confluent monolayers of HeLa cells, stably transfected
CHO-CAR cells, or CHO-control cells transfected with
empty pcDNA3.1 vector were plated in 96-well Costar
dishes. In experiments with enteroviruses maintained in
the laboratory of P.P.L., cell monolayers were exposed to
a 50-ml aliquot of serial twofold dilutions of virus, and
ncubated at room temperature for 1 h. Cell monolayers
ere washed and were further incubated at 37°C. Cyto-
athic effect was monitored after 3 days by removing the
upernatant and staining the cells with a 2% formalde-
yde/0.1% crystal violet dye solution. For SVDV, the ex-
eriments were performed as described above except
hat serial 10-fold dilutions of virus were tested. For CVBs
aintained in the laboratory of J.F.M., confluent cell
onolayers in 24-well plates were exposed to a 100-ml
liquot of virus for 1 h at 37°C. Monolayers were washed
nd were further incubated at 37°C and examined for
ytopathic effect over 6 days.
oluble CAR blocking of CVB-induced cytopathic
ffect
For production of soluble CAR immunoadhesin (sCAR),
NA encoding the CAR extracellular domain (ending
ith PPSNK) was fused to DNA encoding the Fc region of
abbit immunoglobulin, derived from plasmid pKZ374
provided by Dr. John Young, Harvard Medical School)
nd was inserted in the mammalian expression vector
cDNA 3.1 (Invitrogen). Fusion protein was purified from
he supernatant of transiently transfected 293 cells by
hromatography on protein A–Sepharose (Zingler and
oung, 1996). The control immunoadhesin, avian leuko-
is virus envelope glycoprotein fused to rabbit Fc (ALV–
nv) was produced using plasmid pKB201 provided by
r. Young. For sCAR blocking of CVB3-induced CPE,
CAR (or control) was added to a fixed concentration of
irus and was warmed to 37°C for 1 h. The mixture was
hen added to confluent monolayers of HeLa cells plated
n 96-well plates. Monolayers were examined after 24 h
or cytopathic effect by staining cells using the methods
escribed above.
tudies with SVDV
SVDV-induced cytopathic effect was monitored on
AR-positive monolayers of HeLa cells, porcine ST and
K-15 cells, stably transfected CHO-CAR cells, and CAR-
egative CHO-control cells transfected with empty
cDNA3.1, using the methods described above for CVB.
or antibody blocking experiments, stable CHO-CAR
ransfectants or HeLa cells were preincubated with anti-
AR MAb RmcB or anti-DAF MAb 914 or antibody to
ovine albumin (control) and then were infected with
50 PFU/ml of SVDV. Infection was monitored by plaque
ssay. The ability of soluble CAR to block SVDV-inducedPE of HeLa cells was performed as described above for
VB.
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